Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Rhea-AI Summary

Alpine Immune Sciences (NASDAQ: ALPN) has announced that an abstract for the NEON-1 clinical trial results of davoceticept (ALPN-202) will be presented at the AACR Annual Meeting in New Orleans from April 8-13, 2022. This Phase 1 clinical trial focuses on the monotherapy dose escalation of davoceticept in patients with advanced malignancies. The presentation is scheduled for April 12 from 2:30 pm to 4:30 pm CDT, showcasing promising outcomes as Alpine progresses in its immunotherapy development.

Positive

• Abstract accepted for presentation at AACR Annual Meeting, enhancing visibility.
• Davoceticept (ALPN-202) shows superior efficacy in preclinical studies compared to traditional checkpoint inhibitors.
• Phase 1 trial NEON-1 is progressing towards completion of dose escalation and initiation of expansion cohorts.

Negative

• NEON-2 trial is currently on partial clinical hold, which could delay further development.

- NEON-1 Data Selected for Minisymposium Oral Presentation -

SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans to be held April 8–13, 2022.

Results from the dose escalation portion of NEON-1, a Phase 1 clinical trial of davoceticept (ALPN-202) as monotherapy will be presented in a Minisymposium as follows:

Presentation Title: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
Session Title: Immunotherapy Combination Strategies in Clinical Trials
Session Date, Time: Tuesday, April 12, 2:30pm–4:30pm CDT
Presentation Number: CT041

The abstract for the oral presentation will be live on the AACR website on April 8. A copy of the oral presentation slides will be available on the Scientific Publications page of Alpine’s website on April 12 following the presentation.

About Davoceticept (ALPN-202)

Davoceticept (ALPN-202) is a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. Preclinical studies of davoceticept have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone. Completion of dose escalation and initiation of expansion cohorts of NEON-1 (NCT04186637), a Phase 1 monotherapy dose escalation and expansion trial in patients with advanced malignancies, is anticipated in the first half of 2022. NEON-2 (NCT04920383), a combination trial of davoceticept (ALPN-202) and pembrolizumab was initiated in June 2021 and is currently on partial clinical hold.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies; the timing of and results from clinical trials; and the potential efficacy, safety profile, future development plans and regulatory success of our product candidates. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including the impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our product candidates; the partial clinical hold on our NEON-2 trial may not be lifted in a timely manner or at all; our ongoing discovery and preclinical efforts may not yield additional product candidates; our discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of our product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006156/en/

Alex Sharif

Director, Investor Relations and Corporate Development

Alpine Immune Sciences, Inc.

206-788-4545

ir@alpineimmunesciences.com

Media Relations

Kelli Perkins

kelli@redhousecomms.com

Source: Alpine Immune Sciences Inc.

FAQ

What is the NEON-1 trial for Alpine Immune Sciences (ALPN)?

The NEON-1 trial is a Phase 1 clinical trial evaluating the monotherapy dose escalation of davoceticept (ALPN-202) in patients with advanced malignancies.

When will the results of the NEON-1 trial be presented?

The NEON-1 trial results will be presented at the AACR Annual Meeting in New Orleans on April 12, 2022, from 2:30 pm to 4:30 pm CDT.

What are the implications of the NEON-2 trial being on partial clinical hold for ALPN?

The partial clinical hold on the NEON-2 trial may delay the development of combination therapies involving davoceticept (ALPN-202) and pembrolizumab.

What is davoceticept (ALPN-202)?

Davoceticept (ALPN-202) is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor designed for cancer treatment.